Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ABL001/Asciminib

Phase 2Small molecule

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

CMLRecruiting

CMLPhase 2

Recruiting

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

CML

NCT06514534

Clinical

Trials by Indication[1]

CML1 trial

Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.

Recruiting· Novartis logo

Novartis·Phase 2·NCT06514534·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ABL001/Asciminib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ABL001/Asciminib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ABL001/Asciminib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Novartis

Related News